Clearside Biomedical (NASDAQ: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced that it has closed the sale of 4,209,050 shares of common stock. The shares were priced at $2.851 per share, with the sale resulting in approximately $12 million. In the announcement, Clearside noted that the sale took place with institutional investors and certain existing stockholders. Clearside is recognized for its proprietary SCS Microinjector(R), designed to combat sight-threatening disease. The SCS Microinjector targets the suprachoroidal space (“SCS”) and provides access to the macula, retina and choroid. The sole placement agent for the offering was Roth Capital Partners.
To view the full press release, visit https://ibn.fm/X1qzU
About Clearside Biomedical Inc.
Clearside Biomedical is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector(R) targets the suprachoroidal space (“SCS”) and offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. Clearside’s SCS injection platform is an inherently flexible, in-office, nonsurgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations such as gene therapy. For more information about the company, please visit www.ClearsideBio.com.
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork